Evidence map›Paper›PMID 40621822›Full record

ReviewFuture medicinal chemistry2025

Narcotics through time: exploring historical origins, synthetic advances, and clinical progress.

Rakesh Chandra Kalita, Shivank Sharma, Suman Samanta, Deepshikha Patle

Abstract readReviewHistorical Article
In one paragraph

Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rakesh Chandra KalitaSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Shivank SharmaSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Suman SamantaSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Deepshikha PatleSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.ORCID 0000-0003-0127-2123

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pain management has remained one of the most critical challenges in clinical medicine over the past several decades, with narcotics continuing to play a central role in controlling moderate to severe pain. Originating from natural sources such as Papaver somniferum, these compounds have evolved significantly from plant-derived alkaloids to highly potent synthetic opioids. However, despite their therapeutic effectiveness, long-standing concerns such as addiction, tolerance, and life-threatening side effects remain major obstacles. This review presents a comprehensive overview of the historical development of narcotics and recent progress in synthetic pain-relief agents. A broad literature survey was conducted, encompassing peer-reviewed articles, clinical trial data, and historical records, complemented by an independent SAR analysis based on the chemical structures of some of the most potent synthetic derivatives reported to date. Key transitions from traditional opioids to synthetic compounds such are explored, alongside novel clinical advancements like Oliceridine (TRV-130), NKTR-181, and Cebranopadol, which demonstrate promising analgesic efficacy with fewer adverse effects. Additionally, recent preclinical studies on synthetic mu-opioid receptor agonists and dual-receptor targeting compounds are discussed for their therapeutic potential. Overall, ongoing research into safer and more effective synthetic opioids offers a hopeful path forward in advancing analgesic therapy.

Indexed as

Analgesics, OpioidNarcoticsPainAnimalsHistory, 20th CenturyHistory, 21st CenturyHumansReceptors, Opioid, muAnalgesics, OpioidNarcoticsReceptors, Opioid, muanalgesic therapybiased mu-opioid receptor agonistsclinical studieshistorical perspectiveNarcoticspain managementsynthetic derivatives

Identifiers

PMID40621822
PMCPMC12309539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.